Secreted protein, acidic and rich in cysteine is crucial for the vascular endothelial growth factor-stimulated fibrotic process in human Tenon’s fibroblasts

CURRENT STATUS: UNDER REVIEW

XiaoQiong Xiang
Shanghai Jiaotong University the First People's Hospital

LiYing Luo
Shanghai Jiaotong University First People's Hospital

YuHong Chen
Shanghai Jiaotong University the First People's Hospital

FuXiang Ye
Shanghai Jiaotong University the First People's Hospital

Yang Fu
Shanghai Jiaotong University First People's Hospital

Min Tang
Shanghai Jiaotong University the First People's Hospital

Corresponding Author
tangmin_dr@sina.com

DOI:
10.21203/rs.2.14174/v1

SUBJECT AREAS
Ophthalmology

KEYWORDS
Human Tenon’s fibroblast (HTF); secreted protein, acidic and rich in cysteine (SPARC); vascular endothelial growth factor (VEGF); fibrosis
Abstract
Background Aberrant post-surgical scarring is responsible for failure of glaucoma filtration surgery (GFS) and is attributed to strong fibrotic process of human Tenon’s fibroblasts (HTFs). Vascular endothelial growth factor (VEGF) and secreted protein, acidic and rich in cysteine (SPARC) contribute to angiogenesis and fibrosis. However, whether SPARC can regulate the VEGF-mediated fibrotic process in HTFs has not been clarified. This study aimed to examine how SPARC and VEGF crosstalk to regulate the expression of Collagen-I and matrix metalloproteinase 9 (MMP9) as well as the ERK signalling in HTFs.

Methods Human Tenon’s capsule tissues were cultured for preparation of HTFs, which were characterized by immunofluorescence. The effects of VEGF treatment on SPARC, Collagen-I and MMP9 expression and ERK phosphorylation were determined by Western blot, quantitative RT-PCR and immunofluorescence. The proliferation and wound healing induced by VEGF were examined in HTFs and SPARC-silenced HTFs.

Results Following successful passages, immunofluorescent assays indicated that HTFs at passages 3-9 displayed unique characters of fibroblasts with Vimentin, but not keratin, expression. Treatment with VEGF significantly up-regulated SPARC, Collagen-I and MMP9 expression and ERK phosphorylation, and promoted the proliferation and wound healing of HTFs. The stimulatory effects of VEGF were significantly mitigated by SPARC silencing in HTFs.

Conclusions Our data provided novel evidence that SPARC was crucial for the VEGF-stimulated fibrotic process in HTFs and may be a novel target for anti-fibrotic therapies post GFS.

Background
Glaucoma can cause irreversible blindness and it may affect several millions of people in the near future. Filtration surgery (FS) for glaucoma is usually effective. However, surgical failure occurs when excessive wound healing happens below the conjunctiva because human Tenon’s fibroblasts (HTFs) can activate and proliferate, contributing to fibrotic process. Actually, many cytokines and biochemical factors can activate HTFs and promote their fibrotic process, leading to an aberrant scarring response. Thus, understanding the pathogenic process in HTFs will be of significance in
uncovering a new therapeutic target for prevention and intervention of post-FS scarring.

Vascular endothelial growth factor (VEGF) can regulate angiogenesis and fibrosis, and has been considered to be important for post-FS scar formation. Previous studies have shown that VEGF can promote wound healing of HTFs and scar formation in glaucoma patients. In addition, high concentrations of VEGF were detected in the aqueous humor of glaucoma patients and rabbits following FS. Besides, VEGF can be expressed by fibroblasts and stimulate the proliferation of Tenon’s fibroblasts, contributing to the fibrotic process. However, the molecular mechanisms by which VEGF regulates the fibrotic process in HTFs have not been clarified.

Secreted protein, acidic and rich in cysteine (SPARC) is one of the matricellular proteins that are crucial for scar formation and tissue fibrosis. SPARC can regulate the expression of Collagens and matrix metalloproteinases (MMPs), as well as the extracellular matrix (ECM) remodeling. However, little is known about whether SPARC regulates the VEGF-stimulated fibrotic process in HTFs.

In this study, we prepared and characterized HTFs and tested how VEGF stimulated SPARC, Collagen-I and MMP9 expression and ERK activation as well as the wound healing and proliferation of HTFs. Furthermore, we examined the impact of SPARC silencing on the VEGF-stimulated fibrotic process in HTFs.

Methods

Primary cell culture and quality control

This study was approved by the Ethics Committee of Shanghai General Hospital (Registration number: 2016KY034). All patients signed a written informed consent. Small biopsied Tenon’s capsule specimens were isolated from five patients when they underwent a strabismus surgery. After being washed, the tissues were cultured for preparation of HTFs, as described previously. The HTFs were cultivated in Dulbecco’s Modified Eagle’s medium (DMEM) containing 10% of fetal bovine serum (FBS) and the cells were passaged every 3–5 days. Subsequently, their morphology and purity were examined by immunofluorescence using rabbit-anti-vimentin (1:400, ab92547, abcam), mouse-anti-keratin (1:50, ab185627, abcam), Alexa Fluor 488-conjugated goat-anti-rabbit or Alexa Fluor 647-
conjugated goat-anti-mouse IgG and DAPI staining. HTFs between passage 3 and passage 9 were used for experiments after starving for 24 h.

**Transduction**

HTFs were cultured overnight and transduced with control lentivirus or lentivirus for expression of SPARC-specific shRNA at a multiplicity of infection (MOI) of 10 in the presence of puromycin (4 µg/ml) for four days to generate HTF-NC and HTF-SPARC-shRNA cells, respectively. The second generation of control lentivirus or lentivirus for SPARC-specific shRNA were generated by transfecting 293T cells with pL_shRNA_mKate2-SPARC-543 and Packaging Mix (cat. no. K4975-00, Invitrogen) using lipofectamine 2000 (cat. no. 11668019, Invitrogen) \(^{12}\). The efficacy of SPARC silencing was determined by Western blot.

**Cell viability assay**

Cell viability was measured by MTS assay using a kit, according to the manufacturer’s instruction (Promega G3580). Briefly, HTFs (1×10\(^3\) cells/mL) were cultured in 96-well plates and when reaching 80% confluency, the cells were treated in sextuplicate with vehicle PBS or VEGF (25–100 ng/mL, 96-100–20A–2, PeproTech) for 24 h. Individual wells were added with 20 µL of MTS and cultured at 37°C for 2 h. The absorbance at 490 nm was measured using a microplate reader (Epoch™ Bio-Tek Instruments, Winooski, VT, USA). Additional MTS assays were performed in HTF, HTF-NC and HTF-SPARC-shRNA cells using 50 ng/ml of VEGF for stimulation.

**Western blot**

The impact of VEGF on SPARC and other fibrosis-related protein expression was determined by Western blot. Briefly, HTFs were stimulated with, or without, 25–100 ng/mL of VEGF for 24 h and their cell lysates were prepared. After determination of protein concentrations, cell lysates (50 µg/lane) were analysed by Western blot using primary antibodies against β-actin (1:1000, 60008-1-Ig, Proteintech), SPARC (1:1000, ab207743), Collagen-I (1:1000, ab138942), MMP9 (1:1000, ab76003), ERK1/2 (1:1000; ab184699, abcam) and p-REK1/2 (1:1000, #9101, Cell Signaling Technology) and HRP-goat anti-rabbit IgG (1:5000, #A27024) or HRP-goat anti-mouse IgG (1:5000, #A11357,
Thermofisher) as well as an ECL assay kit. The data were analysed by densitometry using ImageJ software. Additional Western blot assays were performed in HTF, HTF-NC and HTF-SPARC-shRNA cells using 50 ng/ml of VEGF for stimulation.

**Immunofluorescence**

HTFs (1×10³ cells/mL) were grown on glass coverslips in 24-well plates and when reaching 80% confluency, the cells were treated with VEGF for 24 h. The cells were stained with primary antibodies against SPARC, Collagen-I and MMP-9. After being washed, the cells were incubated with Alexa Fluor-488-conjugated secondary antibodies (1:1000, Invitrogen, Carlsbad, CA, USA), followed by nuclearn stained with DAPI. The fluorescent signals were visualized using a confocal microscope (Carl Zeiss). Additional immunofluorescent assays were performed in HTF, HTF-NC and HTF-SPARC-shRNA cells using 50 ng/ml of VEGF for stimulation.

**Quantitative RT-PCR**

The effect of VEGF on SPARC and other fibrosis-related gene mRNA transcripts were determined quantitative RT-PCR using special reagents including TRIzol, the PrimeScript 1st Strand cDNA Synthesis kit (RR036A, TaKaRa Bio, Dalian, China), the SYBR Premix Ex Taq (RR420, TaKaRaBio) in Viia7 Real-Time PCR System (Applied Biosystems, Life Technonogies, Carlsbad, CA, USA). The primer sequences were forward 5’-GGACTTGCAGCAAGAGATGG–3’ and reverse 5’-AGCACTGTGTTGGGCACGTACAG–3’ for β-actin; forward 5’-AGGAAACCGAAGAGGAGG–3’ and reverse 5’-GCAAAGAAGTGCGCAGGAA–3’ for SPARC; forward 5’-GACCTCAAGTGGCACCACCA–3’ and reverse 5’-GTGGTACTGCACCGGCAA–3’ for MMP9; forward 5’-CCCAGCCACAAAGAGTCTACA–3’ and reverse 5’-GTTTCCACACGTCTCGGTCA–3’ for collagen-I. The data were analyzed by 2-ΔΔCt. Additional quantitative RT-PCR assays were performed in HTF, HTF-NC and HTF-SPARC-shRNA cells using 50 ng/ml of VEGF for stimulation.

**Wound healing assay**

HTFs were cultured twelve-well plates. When the cells reached full confluency, they were scratched using a pipette tip. The cells were treated with, or without, 25-100 ng/ml of VEGF and the dynamic
process of cell proliferation and migration was monitored longitudinally by photoimaged. The data were expressed as the percentage of wound healing. Additional wound healing assays were performed in HTF, HTF-NC and HTF-SPARC-shRNA cells using 50 ng/ml of VEGF for stimulation.

**Statistical analysis**

Data are present as the means ± standard deviation (SD). The statistical comparisons were performed by Student’s t-test or ANOVA using SPSS version 17.0 for Windows (SPSS, USA). A P-value of <0.05 was considered statistically significant.

**Results**

**Preparation and characterization of HTFs.**

Following cultured the tissue explants for 10 to 14 days, many cells migrated out and the cells were continually passaged. Immunofluorescence revealed that all cells were positive for anti-vimentin, but negative for anti-keratin staining, the hallmarks of fibroblast-like cells (Fig. 1). We observed that their morphology and growth characteristics were not affected by resuscitation and cryopreservation in our experimental conditions.

**VEGF up-regulates the expression of fibrotic proteins and promotes the proliferation and migration of HTFs**

VEGF can stimulate angiogenesis, inflammation and migration of fibroblasts. To understand the molecular mechanisms underlying the action of VEGF, we examined whether VEGF could modulate the SPARC, Collagen-I, MMP9 expression and ERK1/2 activation in HTFs. Western blot indicated that treatment with 50 ng/ml of VEGF significantly increased the relative levels of SPARC, Collagen-I, MMP9 expression and ERK phosphorylation in HTFs (Fig. 2A). However, treatment with VEGF at a lower or higher dose either did not significantly up-regulate or only moderately increased their expression and phosphorylation in HTFs. Similar patterns of VEGF-enhanced SPARC, Collagen-I and MMP9 expression were observed in HTFs by immunofluorescence (Fig. 2B). Similarly, treatment with VEGF increased the relative levels of SPARC, Collagen-I and MMP9 mRNA transcripts in HTFs (Fig. 2C). Functionally, VEGF treatment significantly promoted the proliferation and wound healing of HTFs (Fig. 2D and E). Hence, VEGF promoted the proliferation and wound healing of HTFs by enhancing fibrotic protein expression.
and ERK1/2 activation in vitro.

**SPARC silencing mitigates the VEGF-induced fibrotic process in HTFs**

SPARC can regulate ECM remodelling by modulating collagen expression and MMP activity\(^9,10\). To understand the regulatory role of SPARC in VEGF-induced fibrotic process in HTFs, we generated stable SPARC-silenced HTFs by lentivirus-based shRNA technology. Following stimulation with VEGF (50 ng/ml), we found that SPARC silencing not only decreased the VEGF-stimulated SPARC expression, but also mitigated the VEGF-enhanced Collagen–1 and MMP expression and ERK phosphorylation in HTFs (Fig. 3A-C). Functionally, measurements of wound healing and cell proliferation revealed that following VEGF stimulation, the percentages of wound healing and viability in the SPARC-silenced HTFs were significantly lower than that in the controls (Fig. 3D and E). Such data indicated that SPARC silencing mitigated the VEGF-stimulated wound healing and proliferation in HTFs *in vitro*. Collectively, these findings suggest that VEGF-stimulated fibrotic process in HTFs may partially depend on inducing SPARC expression in our experimental conditions. Meanwhile, our experiment showed that all the aspect mentioned above of NC HTFs were slightly down regulated compared with normal HTFs. Probably, the process of infecting cells with virus would also affect the function of cells to some extent.

**Discussion**

FS is one of the most effective treatments for glaucoma\(^13\). Unfortunately, a failure in FS for glaucoma occasionally occurs due to excessive post-surgical wound healing process and scar formation. Previous studies have shown that VEGF\(_{121}\) and VEGF\(_{189}\) can induce the proliferation and migration of HTFs by activating the ERK signaling\(^14,5\) and higher levels of VEGF expression in Tenon’s tissues are associated with post-FS fibrosis\(^8\). In this study, we prepared HTFs from human Tenon’s capsule tissues and characterized them. We found that almost all cells displayed typical morphology of fibroblasts with Vimentin, but not keratin, expression. Furthermore, we found that VEGF treatment stimulated the proliferation and wound healing of HTFs, accompanied by up-regulating SPARC, Collagen-I and MMP9 expression and ERK1/2 phosphorylation. Such data clearly demonstrated that
VEGF promoted the fibrotic process of HTFs and suggest that SPARC may participate the process of VEGF-mediated fibrosis.

SPARC is an ECM protein and its up-regulated expression is associated with fibrosis. Actually, \( \text{SPARC-/} \) mice exhibit deficient scarring and SPARC deficiency increases successful rates of FS in a mouse model of Glaucoma \(^{15}\). In this study, we found that treatment with VEGF stimulated SPARC expression in HTFs, which extended previous observations in HMEC-1 cells and HUVECs \(^{16}\). Furthermore, VEGF also up-regulated Collagen-I and MMP9 expression in HTFs and promoted the proliferation and wound healing of HTFs. More importantly, SPARC silencing significantly mitigated the VEGF-stimulated Collagen-I and MMP9 expression in HTFs and attenuated the VEGF-stimulated proliferation and wound healing of HTFs. Previous studies have shown that SPARC can modulate MMP activity in U87MG glioma cells \(^{17}\) and altered MMP activity can affect the ECM remodeling and fibroblast proliferation and migration \(^{18–19}\). Moreover, SPARC can promote cell adhesion \(^{20}\) and SPARC deficiency inhibits cell migration in various types of cells \(^{21–22}\). It is possible that SPARC modulates MMP activity and wound healing, contributing to the progression of fibrosis \(^{23}\). Hence, such data further indicated that SPARC participated in the fibrotic process in HTFs.

It is notable that SPARC can bind to collagen and acts as a chaperone to promote its post-translational process \(^{24, 25}\). Furthermore, SPARC can activate both platelet-derived growth factor (PDGF) and fibroblast growth factor-2 (FGF2), which are crucial for Collagen-I expression \(^{9, 26}\). VEGF can activate the p38 and ERK signaling in vascular endothelial cells \(^{14, 27}\). We found that VEGF treatment enhanced the ERK1/2 phosphorylation in HTFs, consistent with a previous report \(^{14}\). Interestingly, SPARC silencing significantly mitigated the VEGF-enhanced ERK1/2 activation in HTFs. It is possible that SPARC silencing may minimize PDGF and FGF2 activation, which cross-talks with the VEGF-related ERK1/2 signaling to reduce Collagen-I expression and fibrotic process in HTFs. We are interested in further investigating the precise molecular mechanisms underlying the action of SPARC in regulating Collagen-I and MMP9 expression following VEGF stimulation in HTFs.
Conclusions
Our data indicated that VEGF treatment stimulated the wound healing and proliferation of HTFs by up-regulated SPARC, Collagen-I and MMP9 expression and ERK phosphorylation, which were significantly mitigated by SPARC silencing. Such data suggest that SPARC may be crucial for the VEGF-stimulated fibrotic process in HTFs. Conceivably, SPARC may be a valuable therapeutic target for prevention and invention of FS-related scarring.

List Of Abbreviations
GFS: Glaucoma Filtration Surgery
HTF: Human Tenon’s fibroblast
VEGF: Vascular endothelial growth factor
SPARC: Secreted protein, acidic and rich in cysteine
MMP: Matrix metalloproteinase
FS: Filtration surgery
ECM: Extracellular Matrix

Declarations
Ethics approval and consent to participate
This study was approved by the Ethics Committee of Shanghai General Hospital (Registration number: 2016KY034). All patients signed a written informed consent.

Consent for publication
Not applicable

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing interests.

Funding
This study was supported by a grant from the National Nature Science Foundation of China (Grant No.81700845).
Authors’ contributions
Xiang X, Fu Y, and Tang M were primarily responsible for experimental concept and design. Xiang X, Luo L and Chen Y performed the experiments and data acquisition. Xiang X, Ye F and Fu Y performed the data analysis as well as drafting of the manuscript. All authors reviewed and approved the final manuscript.

Acknowledgement
We are grateful to the Shanghai Key Laboratory of Ocular Fundus Diseases of Shanghai General Hospital for providing the experimental equipments and device.

Authors’ information

Affiliations
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Corresponding author
Correspondence to Min Tang
CO-Correspondence to Yang Fu

Reference
1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90(3):262-7.
2. Masoumpour MB, Nowroozzadeh MH, Razeghinejad MR. Current and Future Techniques in Wound Healing Modulation after Glaucoma Filtering Surgeries. Open Ophthalmol J 2016;10:68-85.
3. Meyer-Ter-Vehn T, Klink T, Grehn F, Schlunck G. [Beyond TGF-beta: wound healing modulation in filtering glaucoma surgery]. Klin Monbl Augenheilkd 2009;226(1):22-6.
4. Zada M, Pattamatta U, White A. Modulation of Fibroblasts in Conjunctival Wound Healing. Ophthalmology 2018;125(2):179-92.
5. Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H.. The role of vascular endothelial growth factor in wound healing. J Surg Res 2009;153(2):347-58.
6. Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, Dipietro LA.. Regulation of scar formation by
vascular endothelial growth factor. Lab Invest 2008;88(6):579-90.

7. Li Z1, Van Bergen T, Van de Veire S, Van de Vel I, Moreau H, Dewerchin M, Maudgal PC, Zeyen T, Spileers W, Moons L, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2009;50(11):5217-25.

8. Li Z, Hua W, Li X, Wang W. Suppression of Human Tenon Fibroblast Cell Proliferation by Lentivirus-Mediated VEGF Small Hairpin RNA. J Ophthalmol 2017;2017:7982051.

9. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2001;19(8):816-27.

10. Ding W, Pu W, Jiang S, Ma Y, Liu Q, Wu W, Chu H, Zou H, Jin L, Wang J, et al. Evaluation of the antifibrotic potency by knocking down SPARC, CCR2 and SMAD3. EBioMedicine 2018;38:238-47.

11. Cai X, Yang Y, Chen P, Ye Y, Liu X, Wu K, Yu M. Tetramethylpyrazine Attenuates Transdifferentiation of TGF-β2-Treated Human Tenon’s Fibroblasts. Invest Ophthalmol Vis Sci. 2016;57(11):4740-8.

12. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply Attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997;15: 871-875.

13. Lama PJ, Fechtner RD. Antifibotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48(3):314-46.

14. Van Bergen T, Vandewalle E, Van de Veire S, Dewerchin M, Stassen JM, Moons L, Stalmans I. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res 2011;93(5):689-99.

15. Seet LF, Su R, Barathi VA, Lee WS, Poh R, Heng YM, Manser E, Vithana EN, Aung T, Weaver M, et al. SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery. PLoS One 2010;5(2):e9415.

16. Kato Y, Lewalle JM, Baba Y, Tsukuda M, Sakai N, Baba M, Kobayashi K, Koshika S, Nagashima Y, Frankenne F, et al. Induction of SPARC by VEGF in human vascular endothelial cells. Biochem Biophys Res Commun 2001;287(2):422-6.

17. McClung HM, Thomas SL, Osenkowski P, Toth M, Menon P, Raz A, Fridman R, Rempel SA. SPARC
upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett 2007;419(2):172-7.

18. Li B, Li F, Chi L, Zhang L, Zhu S.. The expression of SPARC in human intracranial aneurysms and its relationship with MMP-2/-9. PLoS One 2013;8(3):e58490.

19. Cui N, Hu M, Khalil RA. Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog Mol Biol Transl Sci 2017;147:1-73.

20. Tumbarello DA, Andrews MR, Brenton JD. SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells. PLoS One 2016;11(9):e0162698.

21. Chang CH, Yen MC, Liao SH, Hsu YL, Lai CS, Chang KP, Hsu YL. Secreted Protein Acidic and Rich in Cysteine (SPARC) Enhances Cell Proliferation, Migration, and Epithelial Mesenchymal Transition, and SPARC Expression is Associated with Tumor Grade in Head and Neck Cancer. Int J Mol Sci 2017;18(7).

22. Seno T, Harada H, Kohno S, Teraoka M, Inoue A, Ohnishi T. Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol 2009;34(3):707-15.

23. Robert S, Gicquel T, Victoni T, Valença S, Barreto E, Bailly-Maître B, Boichot E, Lagente V.. Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis. Biosci Rep 2016;36(4).

24. McDonald LT, Zile MR, Zhang Y, Van Laer AO, Baicu CF, Stroud RE, Jones JA, LaRue AC, Bradshaw AD. Increased macrophage-derived SPARC precedes collagen deposition in myocardial fibrosis. Am J Physiol Heart Circ Physiol 2018;315(1):H92-h100.

25. Rentz TJ, Poobalarahi F, Bornstein P, Sage EH, Bradshaw AD. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem 2007;282(30):22062-71.

26. Atorrasagasti C, Aquino JB, Hofman L, Alaniz L, Malvicini M, Garcia M, Benedetti L, Friedman SL, Podhajcer O, Mazzolini G. Atorrasagasti C, Aquino JB, Hofman L, et al. SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-beta1 and PDGF. Am J Physiol Gastrointest Liver Physiol 2011;300(5):G739-48.

27. Almalki SG, Agrawal DK. ERK signaling is required for VEGF-A/VEGFR2-induced differentiation of
porcine adipose-derived mesenchymal stem cells into endothelial cells. Stem Cell Res Ther 2017;8(1):113.

Figures

Figure 1
Immunofluorescent characterization of HTFs. Human Tenon's specimens were cultured for 15 days and many cells migrated out. The cells were passaged every 3 days for 3-9 times. The cells were stained with anti-Vimentin or anti-keratin, and after being washed, the cells were stained with Alexa Fluor 488-conjugated goat-anti-rabbit IgG or Alexa Fluor 647-conjugated goat-anti-mouse IgG. Subsequently, the cells were nuclearly stained with DAPI and the fluorescent signals were captured under a confocal microscope. Data are representative images (magnification x 200) from three separated experiments. (A) Immunofluorescent staining of cells with anti-Vimentin. (B) Immunofluorescent staining with anti-keratin. Scale bar: 100 μm.
VEGF stimulates SPARC, Collagen-I and MMP9 expression and ERK phosphorylation to promote the proliferation and wound healing in HTFs. HTFs were starved overnight and stimulated in triplicate or sexuplicate with the indicated concentrations of VEGF for 24 h.

(A) The relative levels of SPARC, Collagen-I and MMP9 expression and ERK1/2 phosphorylation were determined by Western blot. (B) The expression of SPARC, Collagen-I and MMP9 was characterized by immunofluorescence. (C) The relative levels of SPARC, Collagen-I and MMP9 mRNA transcripts were quantified by quantitative RT-PCR. (D) The wound healing. (E) The viability of HTFs was examined by MTS assays. Data are representative images or expressed as the mean ± SD of each group of cells from three separate experiments. *P < 0.05; **P < 0.01.
Figure 3

SPARC silencing mitigates the VEGF-stimulated fibrotic process in HTFs. HTFs, control HTF-NC and stable SPARC-silenced HTF-SPARC-shRNA cells were starved overnight and stimulated in triplicate or sexuplicate with 50 ng/ml of VEGF for 24 h. (A) The relative levels of SPARC, Collagen-I and MMP9 expression and ERK1/2 phosphorylation were determined by Western blot. (B) The expression of SPARC, Collagen-I and MMP9 was characterized by immunofluorescence. (C) The relative levels of SPARC, Collagen-I and MMP9 mRNA transcripts were quantified by quantitative RT-PCR. (D) The wound healing. (E) The viability of HTFs was examined by MTS assays. Data are representative images or expressed as the mean ± SD of each group of cells from three separate experiments. *P < 0.05; **P < 0.01.